A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford researchers in the Lin Lab have identified kinase-modulated bioluminescent indicators (KiMBIs) which can assess real time kinase inhibition in target tissues in vivo.
The inventors discovered that a known small molecule tyrosine kinase inhibitor may correct the errant signaling pathways in the rare diseases Hereditary Hemorrhagic Telangiectasia (HHT) and Pulmonary Arterial Hypertension (PAH).